Properdin Levels in Individuals with Chemotherapy-Induced Neutropenia

Tsyrkunou, Artsiom; Agarwal, Sakshi; Koirala, Bibek; Finberg, Robert W.; Nath, Rajneesh; Barton, Bruce; Levitz, Stuart M.; Wang, Jennifer; Ram, Sanjay

doi:10.1093/ofid/ofw250

Cited by 4 publications

(1 citation statement)

References 28 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Properdin levels are reduced by ~19-32% in neutropenic states in patients under chemotherapy. This indicates the importance of neutrophils in contributing to serum properdin levels, while also suggesting significant contribution of other cells as well (Tsyrkunou, et al, 2017).…”

Section: Properdin Sourcesmentioning

confidence: 79%

Properdin: A multifaceted molecule involved in inflammation and diseases

Chen

Cortés

Ferreira

2018

Molecular Immunology

View full text Add to dashboard Cite

Properdin, the widely known positive regulator of the alternative pathway (AP), has undergone significant investigation over the last decade to define its function in inflammation and disease, including its role in arthritis, asthma, and kidney and cardiovascular diseases. Properdin is a glycoprotein found in plasma that is mainly produced by leukocytes and can positively regulate AP activity by stabilizing C3 and C5 convertases and initiating the AP. Promotion of complement activity by properdin results in changes in the cellular microenvironment that contribute to innate and adaptive immune responses, including pro-inflammatory cytokine production, immune cell infiltration, antigen presenting cell maturation, and tissue damage. The use of properdin-deficient mouse models and neutralizing antibodies has contributed to the understanding of the mechanisms by which properdin contributes to promoting or preventing disease pathology. This review mainly focusses on the multifaceted roles of properdin in inflammation and diseases, and how understanding these roles is contributing to the development of new disease therapies.

show abstract

Section: Properdin Sourcesmentioning

confidence: 79%

Properdin: A multifaceted molecule involved in inflammation and diseases

Chen

Cortés

Ferreira

2018

Molecular Immunology

View full text Add to dashboard Cite

show abstract

The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?

et al. 2018

View full text Add to dashboard Cite

Properdin is known as the only positive regulator of the complement system. Properdin promotes the activity of this defense system by stabilizing its key enzymatic complexes: the complement alternative pathway (AP) convertases. Besides, some studies have indicated a role for properdin as an initiator of complement activity. Though the AP is a powerful activation route of the complement system, it is also involved in a wide variety of autoimmune and inflammatory diseases, many of which affect the kidneys. The role of properdin in regulating complement in health and disease has not received as much appraisal as the many negative AP regulators, such as factor H. Historically, properdin deficiency has been strongly associated with an increased risk for meningococcal disease. Yet only recently had studies begun to link properdin to other complement-related diseases, including renal diseases. In the light of the upcoming complement-inhibiting therapies, it is interesting whether properdin can be a therapeutic target to attenuate AP-mediated injury. A full understanding of the basic concepts of properdin biology is therefore needed. Here, we first provide an overview of the function of properdin in health and disease. Then, we explore its potential as a therapeutic target for the AP-associated renal diseases C3 glomerulopathy, atypical hemolytic uremic syndrome, and proteinuria-induced tubulointerstitial injury. Considering current knowledge, properdin-inhibiting therapy seems promising in certain cases. However, knowing the complexity of properdin's role in renal pathologies in vivo, further research is required to clarify the exact potential of properdin-targeted therapy in complement-mediated renal diseases.

show abstract